Medical cannabis regulation: an overview of models around the world with emphasis on the Brazilian scenario
Tóm tắt
Cannabis sativa has accompanied humankind since ancient times, permeating the most diverse aspects of its existence, among which the search for health promotion and well-being stands out. Nevertheless, during the twentieth century, a series of restrictions and controls have been adopted internationally to prevent the abusive use of this species. Despite that, there has been an increased demand for the medical use of cannabis and its derivatives in the last few decades, especially among patients with debilitating conditions for which the existing therapeutic alternatives are limited. Accordingly, several countries have adopted regulatory strategies to allow access to cannabis-based products. This study aimed to overview the existing regulatory frameworks for medical cannabis around the world, focusing on the current Brazilian scenario. In addition to supply and access regulation aspects, some quality-related issues regarding cannabis-based pharmaceutical products were addressed, with emphasis on risks to patients. The literature research was performed between October 2020 and March 2021. According to the retrieved information, by the time the data collection was completed, thirty-six countries had already implemented regulatory frameworks regarding medical cannabis, and sixteen countries had models under development or in the process of implementation. The characteristics of the assessed regulatory strategies vary considerably from country to country, reflecting sociocultural, historical, and political aspects. Among the key aspects that differed between the assessed models, one can highlight the type of cannabis products that are made available and the technical requirements applied to them, as well as the possible access mechanisms. Different supply regulation strategies were also observed regarding cannabis cultivation, production licensing, and distribution mechanisms. In Brazil, an evolution of the regulatory framework has been noticeable since 2015, even though pending points are still to be addressed, among which are the species’ cultivation and the access to it for scientific research purposes. Constructing a regulatory model which provides access to good quality cannabis-based medicines that may meet the patient’s needs is still a challenge in the coming years, requiring the engagement of various stakeholders, including regulators, members of the academic community, prescribing professionals, and patients.
Tài liệu tham khảo
Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products – regulations in Europe and North America. Eur J Internal Medi. 2018;49:2–6.
Agência Nacional de Vigiância Sanitária. Nota Técnica no 01/2017/GMESP/GGMED/ANVISA. Agência Nacional de Vigilância Sanitária. Brasília; 2017. p. 1–4.
Agência Nacional de Vigiância Sanitária. RDC n. 335 de 24 de janeiro de 2020. Imprensa Nacional: Diário Oficial da União. Brasília; 2020. p. 54.
Agência Nacional de Vigilância Sanitária. RDC no 03 de 26 de janeiro de 2015. Imprensa Nacional: Diário Oficial da União Brasília; 2015a. p. 53.
Agência Nacional de Vigilância Sanitária. RDC no 17 de 6 de maio de 2015. Imprensa Nacional: Diário Oficial da União. Brasília; 2015b. p. 50.
Agência Nacional de Vigilância Sanitária. RDC no 130 de 2 de dezembro de 2016. Imprensa Nacional: Diário Oficial da União. Brasília; 2016.
Agência Nacional de Vigilância Sanitária. RDC n. 327 de 9 de dezembro de 2019. Imprensa Nacional: Diário Oficial da União Brasília; 2019. p. 194.
Aguilar S, Gutiérrez V, Sánchez L, Nougier M. Medicinal cannabis policies and practices around the world. Int Drug Policy Consortium. 2018:32.
Alves M. The Natural Fallacy in a Post-Truth era. EMBO Rep. 2020;21(2):e49859.
Alves P, Amaral C, Teixeira N, Correia-da-Silva G. Cannabis sativa: much more beyond Δ9-tetrahydrocannabinol. Pharmacol Res. 2020;157:104822. https://doi.org/10.1016/j.phrs.2020.104822.
Bacchi A. “Farmacofobia”: o irracional avesso da (hiper)medicalização: Revista Questão de Ciência; 2020. Available from: http://revistaquestaodeciencia.com.br/artigo/2020/11/06/farmacofobia-o-irracional-avesso-da-hipermedicalizacao [cited 5 May 2022]
Belackova V, Shanahan M, Ritter A. Mapping regulatory models for medicinal cannabis: a matrix of options. Austr Health Rev. 2018;42(4):403–11.
Berkovic SF. Cannabinoids for epilepsy - real data, at last. N Engl J Med. 2017;376(21):2075–6.
Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995–1010 Available from: http://www.thelancet.com/article/S2215036619304018/fulltext [cited 20 Dec 2021].
Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, et al. Cannabis sativa: a comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 2018;227:300–15.
BRASIL. Ministério das Saúde. Agência Nacional de Vigilância Sanitária. Portaria n. 344, de 12 de maio de 1998: Diário Oficial da União; 1998. p. 29.
Brasil. Lei no 11.343, de 23 de agosto de 2006. Brasil: Diário Oficial da União, 11.343; 2006. Available from: http://www.planalto.gov.br/ccivil_03/_ato2004-2006/2006/lei/l11343.htm
Brasil. Câmara dos deputados. PROJETO DE LEI No 399 de 02 de fevereiro de 2015. Brasília: Câmara dos deputados; 2015. p. 1–4. Available from: https://www.camara.leg.br/proposicoesWeb/fichadetramitacao?idProposicao=947642
Bureau voor Medicinale Cannabis. Monograph cannabis flos version 7.1. OMC/ Farmalyse BV version 7.1. 2014. Available from: https://www.cannabisbureau.nl/arts-en-apotheker/documenten/richtlijnen/2017/12/01/monograph-cannabis-flos
Bureau voor Medicinale Cannabis. Uitleg gesloten productieketen Medicinale Cannabis. Bureau voor Medicinale Cannabis. Available from: https://www.cannabisbureau.nl/pers/uitleg-gesloten-productieketen-bmc. [cited 15 Mar 2021]
Cáceres Guido P, Riva N, Calle G, Dell’Orso M, Gatto M, Sberna N, et al. Medicinal cannabis in Latin America: History, current state of regulation, and the role of the pharmacist in a new clinical experience with cannabidiol oil. J Am Pharm Assoc. 2020;60(1):212–5.
Chow R, Valdez C, Chow N, Zhang D, Im J, Sodhi E, et al. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Support Care Cancer. 2020;28(5):2095–103 Available from: https://link.springer.com/article/10.1007/s00520-019-05280-4 [cited 20 Dec 2021].
Crippa JAS, Crippa ACS, Hallak JEC, Martín-Santos R, Zuardi AW. Δ9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Front Pharmacol. 2016;7:1–6.
de Oliveira MB, Vieira MS, Akerman M. Cannabis self-cultivation and social technology. Saúde Soc. 2020;29(3).
Deutsches Arzneibuch. Cannabisblüten (Cannabis flos). Vol. 1998, vol. 2005.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376(21):2011–20.
Dinis-Oliveira RJ. The clinical toxicology perspective on the therapeutic use of cannabis and cannabinoids. Acta Med Portuguesa. 2019;32(2):87–90.
European Medicines Agency. Epidiolex Assessment Report, vol. 31; 2019. p. 190.
European Monitoring Centre for Drugs and Drug Addiction. Cannabis legislation in Europe. 2018a.
European Monitoring Centre for Drugs and Drug Addiction. Medical use of cannabis and cannabinoids: questions and answers for policymaking. Luxembourg: Publications Office of the European Union; 2018b. Available from: http://www.emcdda.europa.eu/system/files/publications/10171/20185584_TD0618186ENN_PDF.pdf [cited 31 Jan 2021]
Expert Committee on Drug Dependence. Annex 1-extract from the report of the 41 st expert committee on drug dependence: cannabis and cannabis-related substances; 2019. p. 1–8.
Food and Drug Administration. Botanical drug development - guidance for industry: U.S. Department of Health and Human Services. Silver Spring; 2016. p. 1–30.
Food and Drug Administration. Approval Letter. Application number 210365Orig1s000. 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000Approv.pdf
Giancaspro GI, Kim NC, Venema J, de Mars S, Devine J, Celestino C, et al. Stimuli to the revision process: the advisability and feasibility of developing USP standards for medical cannabis. Pharmacopeial Forum. 2016;42(1):1–8.
Government of Australia. Explanatory Statement - Therapeutic Goods Order No. 93 (Standard for Medicinal Cannabis), vol. 1989; 2016. p. 1–4. Available from: https://www.legislation.gov.au/Details/F2017L00286/Explanatory%20Statement/Text [cited 16 May 2022]
Health Products Regulatory Authority. Cannabis for medical use - a scientific review; 2017. p. 1–83. Available from: https://www.hpra.ie/homepage/about-us/publications-forms/newsletters/item?id=7cb50726-9782-6eee-9b55-ff00008c97d0
Hillig KW. A chemotaxonomic analysis of terpenoid variation in cannabis. Biochem Syst Ecol. 2004;32(10):875–91.
Kalant H, Porath-waller AJ. Dissiper la fumée entourant le cannabis: usage de cannabis et de cannabinoïdes à des fins médicales; 2016.
Klieger SB, Gutman A, Allen L, Pacula RL, Ibrahim JK, Burris S. Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Addiction. 2017;112(12):2206–16.
Koltai H, Namdar D. Cannabis phytomolecule “entourage”: from domestication to medical use. Trends Plant Sci. 2020;25(10):976–84.
Koltai H, Poulin P, Namdar D. Promoting cannabis products to pharmaceutical drugs. Eur J Pharm Sci. 2019;132:118–20.
Kowal M, Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2010–2014. Mult Scler. 2016;6:1515.
Krcevski-Skvarc N, Wells C, Häuser W. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. Eur J Pain. 2018;22(3):440–54.
Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacology. 2022;107(3–4):131–49 Available from: www.karger.com/pha [cited 10 Mar 2022].
MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Internal Med. 2018;49:12–9. https://doi.org/10.1016/j.ejim.2018.01.004.
Mackay R, Phillips K. La réglementation de la marijuana au Canada et ailleurs dans le monde. Otawa: Bibliothèque du Parlement; 2016.
Madras BK. Update of cannabis and its medical use. Alcohol Drug Abuse Res. 2015;5(37):1–41.
Medicinal Cannabis Agency. Guideline on the regulation of medicinal cannabis in New Zealand. 2020.
New Zealand. Misuse of drugs (medicinal cannabis) regulations 2019. LI 2019/321 Ministry of Health; 2019. p. 6–9.
Oliveira MB. A regulamentação do canabidiol no Brasil: como nasce a expertise leiga | Cannabidiol regulation in Brazil: how lay expertise is born. Liinc em Revista. 2017;13(1):190–204.
Pisanti S, Bifulco M. Modern history of medical cannabis: from widespread use to prohibitionism and back. Trends Pharmacol Sci. 2017;38(3):195–8.
Robert Clarke MM. Cannabis: evolution and ethnobotany. Press U of C, editor; 2013. p. 452.
Rocha ED, Silva VEA, Pereira FCS, Jean VM, Souza FLC, Baratto LC, et al. Pharmacognosy qualitative terpene profiling of cannabis varieties cultivated for medical purposes. Rodriguésia. 2020;71.
Russo EB. Current therapeutic cannabis controversies and clinical trial design issues. Front Pharmacol. 2016;7:309.
Rychert M, Wilkins C, Noller G. Medicinal Cannabis Scheme in New Zealand: lessons from international experience and our own recent drug policy reform setbacks. N Z Med J. 2019;132(1503):8–12.
Santé Canada. Un cadre pour la légalisation et la réglementation du cannabis au Canada. Ottawa: Gouvernement du Canada; 2016.
Santé Canada. Règlement sur l ’ accès au cannabis à des fins médicales: Consolidation Codification. Ottawa: Gouvernement du Canada; 2019. p. 2018–20.
Sarma ND, Waye A, Elsohly MA, Brown PN, Elzinga S, Johnson HE, et al. Cannabis inflorescence for medical purposes: USP considerations for quality attributes. J Nat Prod. 2020;83(4):1334–51.
Schlag AKK. An evaluation of regulatory regimes of medical cannabis: what lessons can be learned for the UK? Med Cannabis Cannabinoids. 2020;3(1):76–83.
Seddon T, Floodgate W. Regulating cannabis. Cham: Springer International Publishing; 2020. Available from: http://link.springer.com/10.1007/978-3-030-52927-7
Small E. Evolution and classification of cannabis sativa (Marijuana, Hemp) in relation to human utilization. Botan Rev. 2015;81(3):189–294.
South African Health Products Regulatory Authority. Cultivation of cannabis and manufacture of cannabis-related pharmaceutical products for medicinal and research purposes. 2019.
Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741–53 Available from: https://jnnp.bmj.com/content/89/7/741 [cited 20 Dec 2021].
Sundheds-og Ældreministeriet. Cannabisblomst (Cannabis flos). BEK nr 151. 2019. Available from: https://www.retsinformation.dk/eli/lta/2019/151 [cited 8 Feb 2021]
UN News. UN commission reclassifies cannabis, yet still considered harmful: UN news; 2020. Available from: https://news.un.org/en/story/2020/12/1079132 [cited 25 Feb 2021]
United Nations. Commentary on the single convention on narcotic drugs, 1961. U.N. Secretary General. New York; 1973. p. 1–504.
United Nations Commission on Narcotic Drugs. CND Press Statement –2 December 2020: Press Statement; 2020. p. 2. Available from: https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_63Reconvened/Press_statement_CND_2_December.pdf [cited 14 Dec 2020]
United Nations Office on Drugs and Crime. The international drug control conventions. United Nations, New York; 2013.
Upton R, Craker L, ElSohly M, Romm A, Russo E, Sexton M. Cannabis inflorescence and leaf. In: American Herbal Pharmacopoeia; 2013. p. 1–64.
Whiting PF, Wolff RF, Deshpande S, di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73 Available from: https://jamanetwork.com/ [cited 23 Mar 2022].
World Health Organization. Cannabis and cannabis resin. Report of the thirty-sixth meeting of the WHO Expert Committee on Drug Dependence. 2014.
World Health Organization. The health and social effects of nonmedical cannabis use. 2018. p. Chapter 1.